No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VCYT240816P22500
- 2.00
- +0.07+3.63%
15min DelayTrading Jul 23 11:55 ET
2.00High2.00Low
2.00Open1.93Pre Close1 Volume1 Open Interest22.50Strike Price200.00Turnover78.98%IV14.23%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry2.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3362Delta0.0745Gamma19.92Leverage Ratio-0.0356Theta-0.0056Rho-6.70Eff Leverage0.0226Vega
Intraday
- 5D
- Daily
News
Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT)
Veracyte, Inc.'s (NASDAQ:VCYT) Prospects Need A Boost To Lift Shares
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
Zacks.com Featured Highlights Veracyte, Steelcase and Applied Industrial
Strong Week for Veracyte (NASDAQ:VCYT) Shareholders Doesn't Alleviate Pain of Three-year Loss
Comments
Analysts are slightly more optimistic about Veracyte's losses per share, but expect its revenue growth to slow down substantially compared to its historical 29% growth rate. The wider industry is expected to outpace Veracyte.
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its Annual Results And Analysts Are Updating Their Estimates 1
The absence of any insider transactions in the past three months doesn't reveal much. Low insider ownership and previous insider selling at Veracyte sparks less enthusiasm. Investors should be aware of potential risks associated with the company.
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
10
Gainers:
• $Theravance Biopharma(TBPH.US$ +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
• $Amryt Pharma(AMYT.US$ +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
• $Green Brick Partners(GRBK.US$ +7.3% (to join S&P SmallCap 600)
• $TransGlobe Energy(TGA.US$ +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock...
• $Theravance Biopharma(TBPH.US$ +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
• $Amryt Pharma(AMYT.US$ +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
• $Green Brick Partners(GRBK.US$ +7.3% (to join S&P SmallCap 600)
• $TransGlobe Energy(TGA.US$ +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock...
10
1
Read more